Our Capabilities

Our team applies pharmaceutical industry best practices to the unique challenges of the Cell and Gene Therapy (CGT) field. We can help you with a wide range of needs, spanning from high level corporate strategy development to detailed technical implementation.

Selected Therapeutic Competencies
  • Primary cells and tissues
  • iPSCs, ESCs (incl. gene-modified)
  • HSCs, MSCs (incl. gene-modified)
  • T cells (aβ, γδ, Treg), TILs,
    NK cells, B cells, DCs (incl. gene-modified)
  • Viral gene delivery
    (LVVs, AdVs, AAVs, RVs)
  • Non-viral gene delivery
    (mRNA, exosomes, LNPs, etc.)
  • Gene editing
    (CRISPR/Cas, ZFN, TALEN, etc.)
Case Studies

Core Capabilities In Practice

Reset
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Join the Quarter Horse Newsletter

We’ll send you a quarterly newsletter all things DHC!
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Text Link
No Stage
Text Link
Commercial
Text Link
Pivotal Clinical
Text Link
Early Clinical
Text Link
R&D / Nonclinical
Text Link
Academic
Text Link
Investor
Text Link
Tools, Tech, and Services
Text Link
Therapeutics
Text Link
Cell therapy
Text Link
Gene therapy
Text Link
Biologics
Text Link
Tools / Tech